NCT00239798

Efficacy and Safety of FTY720 in de Novo Adult Renal Transplant Recipients

A 24-month Extension of a One-year, Multicenter, Double Blinded Double Dummy, Randomized Study to Evaluate the Safety and Efficacy of Two Doses of FTY720 Combined With Full-dose Cyclosporine, USP [Modified] (Novartis Brand) and Steroids Versus Mycophenolate Mofetil Combined With Full-dose Cyclosporine, USP [Modified] (Novartis Brand) and Steroids, in Adult de Novo Renal Transplant Recipients

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 255 (planned)
• Sponsor: Novartis Pharmaceuticals · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: —

Summary

This study will evaluate the safety and efficacy of FTY720 combined with cyclosporine and corticosteroids in patients receiving a kidney transplant.

Conditions

• Renal Transplantation

Interventions

Type	Name	Description
DRUG	FTY720

Timeline

• Start date: 2004-11-01
• Primary completion: 2006-11-01
• First posted: 2005-10-17
• Last updated: 2017-02-23